2022 ACC Consensus on Role of Nonstatin Therapies for LDL-Cholesterol Lowering
Since the 2018 guideline’s publication, additional non-statin therapies such as bempedoic acid, evinacumab, and inclisiran, have been approved by the FDA for the management of hypercholesterolemia.
Source: pharmacytimes.com